FMS · Fresenius Medical Care AG & Co. KGaA

Fresenius Medical Care’s Q1 2026 results reflect strong underlying operational execution amid significant strategic investments and regulatory tailwinds. Organic revenue growth of 4% — achieved across all three operating segments — was driven by favorable TDAPA reimbursement effects in U.S. Care Delivery, robust 5008X CAREsystem adoption (now deployed in ~100 clinics with >100,000 treatments), and positive same-market treatment growth internationally (+1.3%). While reported operating income declined 14% to €286 million due to €166 million in FME25+ one-time costs (primarily from U.S. clinic closures), adjusted operating income rose 2% to €467 million, expanding the adjusted margin to 10.1% — the highest in recent quarters. This margin expansion was broad-based: Care Delivery’s adjusted operating income grew 12% to €398 million (12.1% margin), supported by rate and payor mix improvements and TDAPA benefits; Value-Based Care turned around to €9 million adjusted operating income (1.8% margin) on enhanced savings rates; and Care Enablement maintained stable adjusted profitability despite China volume pressures. Management confirmed the full-year 2026 outlook — revenue broadly flat and operating income in a mid-single-digit positive/negative range — signaling confidence in sustained execution of the FME Reignite strategy. The accelerated completion of the €1.0 billion share buyback program (7.9% of capital repurchased by March 31) and continued focus on cash flow generation (operating cash flow up 39% to €227 million) reinforce capital discipline. With the FME25+ program on track to deliver €1.2 billion in cumulative savings by end-2027 and the U.S. clinic optimization progressing as planned, the company is balancing near-term investment costs against durable margin improvement and long-term shareholder value creation.